Insmed Incorporated
- INSM
- NASDAQ
- Biotechnology
- Rare Disease Therapeutics
- Antibiotic (ARIKAYCE)
$96.16
Today −0.11%Quote Oct 19, 2026, 05:00 PM UTC
−22.35%over the last month
Max drawdown −22.4%From 1-month high −22.4%3 months −10.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
1,664
Founded
1988
Market value
$21.00B
Quote Oct 19
Floor
$95.27
0.9% below price
Resistance
$102.01
6.1% above price
Price vs analyst targets
36 analysts
Lowest target
$169.00Highest target
$235.00
$169.00Highest target
$235.00
- Price $96.16
- Average target $196.20
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 104% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about INSMPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free